These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 31114180)

  • 21. Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety.
    Suissa S; Dell'Aniello S; Ernst P
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1975-1986. PubMed ID: 36065315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
    Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
    Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
    Song JH; Lee CH; Kim JW; Lee WY; Jung JY; Park JH; Jung KS; Yoo KH; Park YB; Kim DK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2455-2464. PubMed ID: 28860740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England.
    Sansbury LB; Lipson DA; Bains C; Anley GA; Rothnie KJ; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():415-426. PubMed ID: 35264848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS; DePietro M; McPheeters J; Fox KM
    Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain.
    Alcázar-Navarrete B; García-Rio F; Sánchez G; Mariscal E; García A; Cuesta M; Uría E; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2149-2161. PubMed ID: 34321874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
    Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
    Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
    Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.
    Xu X; Milea D; Navarro Rojas AA; Braganza A; Holbrook T; Marett B; Young R; Scott RJ; Gribben B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1835-1850. PubMed ID: 34177262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world.
    Barnes N; Ishii T; Hizawa N; Midwinter D; James M; Hilton E; Jones PW
    Int J Chron Obstruct Pulmon Dis; 2018; 13():433-440. PubMed ID: 29440882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting.
    Halpin DMG; Rothnie KJ; Banks V; Czira A; Compton C; Wood R; Tritton T; Massey O; Wild R; Snowise N; Nikitin K; Sharma R; Ismaila AS; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2417-2429. PubMed ID: 36185170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of early medication use for COPD: a population-based cohort study.
    Falk J; Dik N; Bugden S
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
    Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
    Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burden of disease associated with a COPD eosinophilic phenotype.
    Ortega H; Llanos JP; Lafeuille MH; Germain G; Duh MS; Bell CF; Sama SR; Hahn B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2425-2433. PubMed ID: 30147308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
    Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.